new_0222_0489|KNTE|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0489|KNTE|1|Kinnate Biopharma Inc Total Current Assets (Quarterly) (USD)|Kinnate Biopharma Inc Cash and Short Term Investments (Quarterly) (USD)|Kinnate Biopharma Inc Inventories (Quarterly) (USD)|Kinnate Biopharma Inc Net PP&E (Quarterly) (USD)|Kinnate Biopharma Inc Goodwill and Intangibles (Quarterly) (USD)|Kinnate Biopharma Inc Total Liabilities (Quarterly) (USD)|Kinnate Biopharma Inc Total Current Liabilities (Quarterly) (USD)|Kinnate Biopharma Inc Total Long Term Liabilities (Quarterly) (USD)|Kinnate Biopharma Inc Total Deposits (Quarterly) (USD)|Kinnate Biopharma Inc Book Value (Quarterly) (USD)|Kinnate Biopharma Inc Retained Earnings (Quarterly) (USD)|Kinnate Biopharma Inc Treasury Stock (Quarterly) (USD)|Kinnate Biopharma Inc EV to Revenues|Kinnate Biopharma Inc EV to Earnings|Kinnate Biopharma Inc EV to Free Cash Flow|Kinnate Biopharma Inc EV to Assets (Quarterly)|Kinnate Biopharma Inc PS Ratio|Kinnate Biopharma Inc PE Ratio|Kinnate Biopharma Inc Price to Book Value|Kinnate Biopharma Inc PEG Ratio|Kinnate Biopharma Inc Debt to Equity Ratio|Kinnate Biopharma Inc Dividend Yield|Kinnate Biopharma Inc Shareholder Yield (TTM)|Kinnate Biopharma Inc Percent of Shares Outstanding Short|Kinnate Biopharma Inc Total Receivables (Quarterly) (USD)|Kinnate Biopharma Inc Total Payables (Quarterly) (USD)|Kinnate Biopharma Inc Total Capital Stock (Quarterly) (USD)|Kinnate Biopharma Inc Return on Invested Capital|Kinnate Biopharma Inc Quality Ratio Score|Kinnate Biopharma Inc Momentum Score|Kinnate Biopharma Inc Beta (1Y)|Kinnate Biopharma Inc Sustainable Growth Rate (TTM)|Kinnate Biopharma Inc Institutional Investor Ownership Percentage|Kinnate Biopharma Inc Average Diluted Shares Outstanding (Quarterly)|Kinnate Biopharma Inc Total Employees (Annual)|Kinnate Biopharma Inc EPS Diluted (Quarterly) (USD)|Kinnate Biopharma Inc SG&A Expense (Quarterly) (USD)|Kinnate Biopharma Inc Shares Outstanding|Kinnate Biopharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Kinnate Biopharma Inc Ordinary Shares Number (Quarterly)|Kinnate Biopharma Inc Payout Ratio|Kinnate Biopharma Inc Quick Ratio (Quarterly)|Kinnate Biopharma Inc Normalized Diluted EPS (Quarterly) (USD)|Kinnate Biopharma Inc Stock Buybacks (Quarterly) (USD)|Kinnate Biopharma Inc Effective Tax Rate (TTM)|Kinnate Biopharma Inc Return on Equity|Kinnate Biopharma Inc Net Income (TTM) (USD)|Kinnate Biopharma Inc Revenue (TTM) (USD)|Kinnate Biopharma Inc Dividend Per Share (Quarterly) (USD)|Kinnate Biopharma Inc Revenue (Quarterly) (USD)|Kinnate Biopharma Inc Gross Profit (Quarterly) (USD)|Kinnate Biopharma Inc Pre-Tax Income (Quarterly) (USD)|Kinnate Biopharma Inc Net Income (Quarterly) (USD)|Kinnate Biopharma Inc Net Interest Income (Quarterly) (USD)|Kinnate Biopharma Inc Price (USD)|Kinnate Biopharma Inc Total Return Price (USD)|Kinnate Biopharma Inc Enterprise Value (USD)|Kinnate Biopharma Inc 30-Day Average Daily Volume|Kinnate Biopharma Inc 1 Year Price Returns (Daily)|Kinnate Biopharma Inc Short Interest|Kinnate Biopharma Inc PE Ratio (Forward)|Kinnate Biopharma Inc PE Ratio (Forward 1y)|Kinnate Biopharma Inc PS Ratio (Forward)|Kinnate Biopharma Inc PS Ratio (Forward 1y)|Kinnate Biopharma Inc Quarterly EPS Estimates (USD)|Kinnate Biopharma Inc Quarterly Revenue Estimates (USD)|Kinnate Biopharma Inc Quarterly EPS Surprise|Kinnate Biopharma Inc Quarterly Revenue Surprise|Kinnate Biopharma Inc Quarterly Actual EPS (USD)|Kinnate Biopharma Inc Quarterly Actual Revenue (USD)|Kinnate Biopharma Inc Revenue Estimates for Current Fiscal Year (USD)|Kinnate Biopharma Inc Revenue Estimates for Next Fiscal Year (USD)|Kinnate Biopharma Inc Price Target (USD)|Kinnate Biopharma Inc Consensus Recommendation|Kinnate Biopharma Inc Price Target Num Estimates|Kinnate Biopharma Inc EPS Estimates for Current Fiscal Year (USD)|Kinnate Biopharma Inc EPS Estimates for Next Fiscal Year (USD)|Kinnate Biopharma Inc Research and Development Expense (Quarterly) (USD)|Kinnate Biopharma Inc Reconciled Depreciation (Quarterly) (USD)|Kinnate Biopharma Inc Non-Operating Interest Expense (Quarterly) (USD)|Kinnate Biopharma Inc Land and Improvements (Quarterly) (USD)|Kinnate Biopharma Inc Buildings and Improvements (Quarterly) (USD)|Kinnate Biopharma Inc Other Properties (Quarterly) (USD)|Kinnate Biopharma Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0489|KNTE|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0489|KNTE|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|monthly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0489|KNTE|5|127.8|127.8||127.8||127.8|127.8|127.8||127.8|127.8||||1.44755244755||||1.44918032787|||1.44918032787||15.2592592593|183|127.8|127.8||||31|||91.2857142857|92|91.2857142857|91.2857142857|31.0909090909||127.8|||91.2857142857|91.4|||91.25|||||91.2857142857|91.2857142857|91.2857142857|1.44918032787|1.44918032787|1.44918032787|1.44565217391|1.45283018868|15.2592592593|||||91.25|91.25|91.5||91.5|91.5|37|40.7|40.7|21.4210526316|40.7|33.9166666667|37|91.2857142857|91.2857142857|||||127.8||
new_0222_0489|KNTE|6|5|5||5||5|5|5||5|5||||286||||305|||305||27|2|5|5||||1|||7|1|7|7|11||5|||7|5|||4|||||7|7|7|305|305|305|276|53|27|||||8|8|2||2|2|11|10|10|19|10|12|11|7|7|||||5||
new_0222_0489|KNTE|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0489|KNTE|201912|77.451|76.453||0.154||95.091|1.945|93.146||-17.486|-17.568||||||||||||||0.973|0.956||||||||23.2827||-0.1693|0.926|||41.0272|||-0.1693|||||||||-3.942|-3.942|0.043||||||||||||||||||||||||3.059||||||0.154||
new_0222_0489|KNTE|202003||||||||||||||||||||||||||||||||||23.2827||-0.1693|0.955||||||-0.1693|||||||||-3.941|-3.941|0.212||||||||||||||||||||||||3.198|0.016|||||||
new_0222_0489|KNTE|202006||||||||||||||||||||||||||||||||||23.2827||-0.327|2.047||||||-0.327|||||||||-7.614|-7.614|0.012||||||||||||||||||||||||5.579|0.02|||||||
new_0222_0489|KNTE|202009|157.479|156.859||0.316||6.699|6.699|||152.498|-39.622|0.075||||||||||||||2.328|0.003|||||||41.0272|27|-0.2559|2.019|||41.0272|||-0.2559||||-25.996|||||-10.499|-10.499|0.004||||||||||||||||||||||||8.484|0.023|||||0.375||
new_0222_0489|KNTE|202012|400.203|396.86||0.368||7.304|7.304|||393.267|-53.329||||-43.7257||||4.3979|||||1.2611||3.94|0.004|||||||43.4774|31|-0.3153|1.743|43.4774||43.4774|||-0.3153|-253.314|||-35.761|||||-13.707|-13.707|0.017|39.78|39.78|1332.671|158883.6||548291|||||-0.3333||||||||52|1.5|4|-1.45|-1.7467|11.976|0.024|||||0.451|32.8|33.43
new_0222_0489|KNTE|202103|251.172|248.197||0.283||7.793|7.793|||378.572|-70.786||||-26.8445||||3.5786|||||3.3334||3.212|0.004|||||||43.4774||-0.4|4.815|43.4774||43.4774|||-0.4||||-49.277|||||-17.457|-17.457|0.403|31.16|31.16|1106.5588|321891.5333||1449257|||||-0.33||-21.2121||-0.4||||52.5|1.5|4|-1.7333|-2.4833|12.666|0.031|||||0.37|26.82|23.48
new_0222_0489|KNTE|202106|258.78|220.008||0.286||43.323|8.323|35||361.34|-92.231||||-15.0389||||2.8105|||||3.5817||1.334|0.004|||||||43.5359||-0.49|5.327|43.6227||43.6227|||-0.49|-0.495|||-63.108|||||-21.445|-21.445|0.672|23.28|23.28|795.5285|128192.1333||1562424|||||-0.4225||-15.9763||-0.49||||51|1.4|4|-1.8825|-2.5625|16.242|0.028|||||0.402|21.58|22.12
new_0222_0489|KNTE|202109|260.712|223.228||0.291||45.299|10.299|35||341.03|-116.933||||-12.5529||||2.9486|||||4.5967||2.724|0.004|||||||43.664||-0.57|6.073|43.6827||43.6827|||-0.57||||-77.311|||||-24.702|-24.702|0.64|23.02|23.02|782.3478|198007.9||2007944|||||-0.535||-6.5421||-0.57||||47|1.2857|6|-2.0633|-2.4683|18.729|0.028|||||0.435|23.77|19.98
new_0222_0489|KNTE|202112|||||||||||||||-8.842||||2.2705|||||3.9612||||||2|0.2172||||||||||||||||||||||||17.72|17.72|551.0669|115861.9|-55.455|1730899|||||-0.575||||||||47.5714|1.2857|7|-1.9917|-2.86||||||||10.98|9
new_0222_0489|KNTE|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.584|||||||||||||||||||||
new_0222_0489|KNTE|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.624|||||||||||||||||||||
new_0222_0489|KNTE|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.668|||||||||||||||||||||
new_0222_0489|KNTE|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.755|||||||||||||||||||||